1. Home
  2. AGPU vs SPRO Comparison

AGPU vs SPRO Comparison

Compare AGPU & SPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Axe Compute Inc. Common Stock

AGPU

Axe Compute Inc. Common Stock

N/A

Current Price

$11.52

Market Cap

83.5M

Sector

N/A

ML Signal

N/A

Logo Spero Therapeutics Inc.

SPRO

Spero Therapeutics Inc.

N/A

Current Price

$1.28

Market Cap

73.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
AGPU
SPRO
Founded
2002
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
83.5M
73.4M
IPO Year
2008
2017

Fundamental Metrics

Financial Performance
Metric
AGPU
SPRO
Price
$11.52
$1.28
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
★ $5.00
AVG Volume (30 Days)
299.0K
★ 697.1K
Earning Date
11-13-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 111.81
EPS
★ N/A
N/A
Revenue
$125,284.00
★ $66,802,000.00
Revenue This Year
$48,110.47
N/A
Revenue Next Year
$614.07
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
★ 39.24
52 Week Low
$1.03
$1.08
52 Week High
$13.49
$3.08

Technical Indicators

Market Signals
Indicator
AGPU
SPRO
Relative Strength Index (RSI) 53.34 47.32
Support Level $7.00 $1.12
Resistance Level $13.48 $1.27
Average True Range (ATR) 0.98 0.07
MACD -0.10 0.01
Stochastic Oscillator 33.56 27.94

Price Performance

Historical Comparison
AGPU
SPRO

About AGPU Axe Compute Inc. Common Stock

Axe Compute Inc functions as an active infrastructure operator. The company intends to expand access to AI compute resources by utilizing the Aethir network, which provides scalable, cost-efficient cloud GPU services for AI, machine learning, gaming, and rendering applications. Through the use of Aethir's decentralized international infrastructure, the company aims to provide access to bare-metal GPUs at scale for both emerging and established organizations.

About SPRO Spero Therapeutics Inc.

Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. It is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

Share on Social Networks: